Journal Article

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Liu, Zhe, Erman, Mustafa, Kalinka-Warzocha, Ewa, Lipatov, Oleg, Botha, Michiel, Araujo, Antonio, Ativitavas, Touch, Popelkova, Patrice, Sugawara, Shunichi, Doganov, Boyan, Ivashchuk, Oleksandr, Torii, Yoshitaro, Dreosti, Lydia, Lazarev, Sergey, Castro, Hugo, Zhang, Xin, Cicenas, Saulius, Cohen, Graham, Seker, Mesut, He, Jianxing, Takahashi, Kazuhisa, Ksienski, Doran, Tanaka, Hiroshi, Ferreira, Carlos, Hsia, Te-Chun, Girotto, Gustavo, Koynov, Krassimir, Duarte, Ricardo, Gomez Wolff, Luis, Landers, Gregory, Beato, Carlos, Juergens, Rosalyn Anne, Yokoyama, Takuma, Cay Senler, Filiz, Kasahara, Kazuo, Murakami, Shuji, Chen, Gongyan, Sriuranpong, Virote, Rappaport, Bernardo, Lopes, Gilberto, Adamchuk, Grigory, Seetalarom, Kasan, Wang, Buhai, Gomez Aubin, Gonzalo, Ho, Chung Man James, Katakami, Nobuyuki, Lopes, Valeria, Zhou, Qing, Cho, Byoung Chul, Miron, Lucian, Stara, Zinaida, Petruzelka, Lubos, Kaen, Diego, Ding, Zhenyu, Hart, Gregory, de The Bustamante Valles, Flor, Varela, Mirta, Wang, Jie, Yamada, Kazuhiko, Aren, Osvaldo, Danchaivijitr, Pongwut, Nakahara, Yasuharu, Kush, Debra, Turdean, Maria, Su, Wu-Chou, de Aze

2019

Overview

First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater. This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater. Randomisation was computer generated, accessed via an interactive voice-response and integrated web-response system, and stratified by region of enrolment (east Asia vs rest of world), ECOG performance status score (0 vs 1), histology (squamous vs non-squamous), and PD-L1 TPS (≥50% vs 1–49%). Enrolled patients were randomly assigned 1:1 in blocks of four per stratum to receive pembrolizumab 200 mg every 3 weeks for up to 35 cycles or the investigator's choice of platinum-based chemotherapy for four to six cycles. Primary endpoints were overall survival in patients with a TPS of 50% or greater, 20% or greater, and 1% or greater (one-sided significance thresholds, p=0·0122, p=0·0120, and p=0·0124, respectively) in the intention-to-treat population, assessed sequentially if the previous findings were significant. This study is registered at ClinicalTrials.gov, number NCT02220894. From Dec 19, 2014, to March 6, 2017, 1274 patients (902 men, 372 women, median age 63 years [IQR 57–69]) with a PD-L1 TPS of 1% or greater were allocated to pembrolizumab (n=637) or chemotherapy (n=637) and included in the intention-to-treat population. 599 (47%) had a TPS of 50% or greater and 818 patients (64%) had a TPS of 20% or greater. As of Feb 26, 2018, median follow-up was 12·8 months. Overall survival was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations (≥50% hazard ratio 0·69, 95% CI 0·56–0·85, p=0·0003; ≥20% 0·77, 0·64–0·92, p=0·0020, and ≥1% 0·81, 0·71–0·93, p=0·0018). The median surival values by TPS population were 20·0 months (95% CI 15·4–24·9) for pembrolizumab versus 12·2 months (10·4–14·2) for chemotherapy, 17·7 months (15·3–22·1) versus 13·0 months (11·6–15·3), and 16·7 months (13·9–19·7) versus 12·1 months (11·3–13·3), respectively. Treatment-related adverse events of grade 3 or worse occurred in 113 (18%) of 636 treated patients in the pembrolizumab group and in 252 (41%) of 615 in the chemotherapy group and led to death in 13 (2%) and 14 (2%) patients, respectively. The benefit-to-risk profile suggests that pembrolizumab monotherapy can be extended as first-line therapy to patients with locally advanced or metastatic non-small-cell lung cancer without sensitising EGFR or ALK alterations and with low PD-L1 TPS. Merck Sharp & Dohme.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Aged / Anaplastic Lymphoma Kinase - drug effects / Anaplastic Lymphoma Kinase - genetics / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Apoptosis / B7-H1 Antigen - metabolism / Cancer / Cancer therapies / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - metabolism / Carcinoma, Non-Small-Cell Lung - pathology / Carcinoma, Non-Small-Cell Lung - secondary / Chemotherapy / Disease-Free Survival / Drug Administration Schedule / Epidermal growth factor receptors / Evidence-based medicine / Far East - epidemiology / Female / Genes, erbB-1 - drug effects / Genes, erbB-1 - genetics / Health care facilities / Histology / Humans / Hyperthyroidism / Hypothyroidism / Immunotherapy / Interactive systems / Kinases / Life expectancy / Life span / Ligands / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - metabolism / Lung Neoplasms - pathology / Lung Neoplasms - secondary / Male / Medical prognosis / Men / Metastases / Metastasis / Middle Aged / Monoclonal antibodies / Mutation / Neoplasm Metastasis - pathology / Oncology / Patients / PD-L1 protein / Pembrolizumab / Platinum / Population / Randomization / Risk assessment / Survival / Targeted cancer therapy / Translocation / Translocation, Genetic / Tumors